Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25084246 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sergey M Deyev und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Swedish Cancer Society, Uppsala University.
Abstract (Originalsprache)
Designed ankyrin repeat protein (DARPin) G3 is an engineered scaffold protein. This small (14.5 kDa) targeting protein binds with high affinity to human epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in several cancers. The use of the DARPin G3 for radionuclide therapy is complicated by its high renal reabsorption after clearance via the glomeruli. We tested the hypothesis that a fusion of the DARPin G3 with an albumin-binding domain (ABD) would prevent rapid renal excretion and high renal reabsorption resulting in better tumour targeting. Two fusion proteins were produced, one with the ABD at the C-terminus (G3-ABD) and another at the N-terminus (ABD-G3). Both variants were labelled with 177Lu. The binding properties of the novel constructs were evaluated in vitro and their biodistribution was compared in mice with implanted human HER2-expressing tumours. Fusion with the ABD increased the retention time of both constructs in blood compared with the non-ABD-fused control. The effect of fusion with the ABD depended strongly on the order of the domains in the constructs, resulting in appreciably better targeting properties of [177Lu]Lu-G3-ABD. Our data suggest that the order of domains is critical for the design of targeting constructs based on scaffold proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
- Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
- Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
- Affibody AB, 171 65 Solna, Sweden.
- Department of Protein Science, KTH-Royal Institute of Technology, 106 91 Stockholm, Sweden.
- Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.
ORCID-Profile: Sergey M Deyev, Maryam Oroujeni, Torbjörn Gräslund, Alia Hani Binti Rosly, Anna Orlova, Alexey Schulga, Anzhelika Vorobyeva, Vladimir Tolmachev
Förderung
- Swedish Research Council
- Swedish Cancer Society
- Uppsala University
- Svenska Sällskapet för Medicinsk Forskning
Zitieren
APA
Deyev, S. M., Oroujeni, M., Garousi, J., Gräslund, T., Li, R., Rosly, A. H. B., Orlova, A., Konovalova, E., Schulga, A., Vorobyeva, A., & Tolmachev, V. (2024). Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084246
Vancouver
Deyev SM, Oroujeni M, Garousi J, Gräslund T, Li R, Rosly AHB, et al. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084246
BibTeX
@article{Deyev2024,
author = {Deyev, Sergey M and Oroujeni, Maryam and Garousi, Javad and Gräslund, Torbjörn and Li, Ruonan and Rosly, Alia Hani Binti and Orlova, Anna and Konovalova, Elena and Schulga, Alexey and Vorobyeva, Anzhelika and Tolmachev, Vladimir},
title = {Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25084246}
}
EUVIMED